Skip to main content

Events

Getting to the heart of it: Improving cardiovascular and renal outcomes in people with CKD and T2D

Getting to the heart of it: Improving cardiovascular and renal outcomes in people with CKD and T2D

This promotional webinar has been developed and funded by the Boehringer Ingelheim & Lilly Alliance and is intended for Healthcare Professionals (HCPs) in the UK and Republic of Ireland only. Promotional information regarding Alliance products will be discussed in this webinar.

Prescribing information for Jardiance® (empagliflozin) for Great Britain Healthcare Professionals is available here

Prescribing information for Jardiance® (empagliflozin) for Northern Ireland Healthcare Professionals is available here

Prescribing information for Jardiance® (empagliflozin) for Healthcare Professionals in the Republic of Ireland is available here

Adverse event reporting information can be found at the bottom of this page.

 

On behalf of the Boehringer Ingelheim and Lilly Alliance and the Primary Care Cardiovascular Society (PCCS), we are delighted to invite you to 'Getting to the heart of it: Improving cardiovascular and renal outcomes in people with CKD and T2D', a webinar taking place on Wednesday 6th December 2023, at 19:00-20:00.
CKD is a major risk factor for CVD. Among people with diabetes, hypertension or CVD, those who also have CKD are at highest risk of adverse outcomes and least likely to receive appropriate treatment1. Please join our expert faculty to learn more about dealing with the treatment challenges associated with these patients. This webinar will be of interest to all healthcare professionals involved in the treatment of these patients. 

 

References: 

  1. Couser WG et al. Kidney Int. 2011;80:1258–1270

This promotional webinar has been developed and funded by the Boehringer Ingelheim & Lilly Alliance and is intended for Healthcare Professionals (HCPs) in the UK and Republic of Ireland only. Promotional information regarding Alliance products will be discussed in this webinar.

Prescribing information for Jardiance® (empagliflozin) for Great Britain Healthcare Professionals is available here

Prescribing information for Jardiance® (empagliflozin) for Northern Ireland Healthcare Professionals is available here

Prescribing information for Jardiance® (empagliflozin) for Healthcare Professionals in the Republic of Ireland is available here

Adverse event reporting information can be found at the bottom of this page.

 

Agenda

Wednesday 6th December 2023

19:00

Introduction

Chair Prof Ahmet Fuat


19:00

CKD burden and EMPA-KIDNEY Trial

  • Dr Kieran McCafferty

19:10

EMPA-REG OUTCOME Trial

  • Dr Janaka Karalliedde

19:20

Empagliflozin: Metabolic benefits and dosing

  • Prof Ahmet Fuat

19:30

Panel Q&A

  • All speakers

20:00

Closing remarks


Agenda subject to change

This promotional webinar has been developed and funded by the Boehringer Ingelheim & Lilly Alliance and is intended for Healthcare Professionals (HCPs) in the UK and Republic of Ireland only. Promotional information regarding Alliance products will be discussed in this webinar.

Prescribing information for Jardiance® (empagliflozin) for Great Britain Healthcare Professionals is available here

Prescribing information for Jardiance® (empagliflozin) for Northern Ireland Healthcare Professionals is available here

Prescribing information for Jardiance® (empagliflozin) for Healthcare Professionals in the Republic of Ireland is available here

Adverse event reporting information can be found at the bottom of this page.

 

Speakers

Dr Kieran McCafferty

Dr Kieran McCafferty

Consultant Nephrologist, Barts Health; Senior Lecturer QMUL

Kieran McCafferty is a Consultant Nephrologist at Barts Health National Health Service Trust and Senior Lecturer at Queen Mary University London. He is an active trialist in the field of cardio renal metabolic disease having led on over 60 trials in the last 5 years.  

He is the Clinical Director of the NIHR Barts Health CRF, the North Thames CRN renal speciality lead, and co chairs the UKKRC CSG on CKD and DKD.


Dr Janaka Karalliedde

Dr Janaka Karalliedde

Clinical Reader in Diabetes and Cardiovascular Disease, School of Cardiovascular Medicine & Sciences at King's College London, Consultant Physician in Diabetes and Endocrinology and Internal Medicine, Guy’s and St Thomas Hospital London

Dr Karalliedde is a Clinical Reader in Diabetes and Cardiovascular Disease in the School of Cardiovascular Medicine & Sciences at King's College London and Consultant Physician in Diabetes and Endocrinology and Internal Medicine at Guy’s and St Thomas Hospital London.  

He graduated with a distinction in medicine from the University of London. He was awarded MRC Clinical Research Training Fellowship and PhD for research on the pathophysiology and treatment of cardiovascular disease and renal disease in diabetes. 

Janaka has a clinical research programme focussing on new treatments to prevent diabetes related renal and cardiovascular complications. In parallel he is an active clinician with specialist clinics for patients with renal and cardiovascular complications of diabetes at Guy’s Hospital and in the community in Lambeth, south London. 


Professor Ahmet Fuat

Professor Ahmet Fuat

PCCS Council Member and former PCCS President, Honorary Professor of Primary Care Cardiology, Durham University, GP, GP Appraiser and GPSI Cardiology, County Durham

Prof Ahmet Fuat PCCS Council Member and former PCCS President, Honorary Professor of Primary Care Cardiology, Durham University, GP, GP Appraiser and GPSI Cardiology, County Durham

Professor Ahmet Fuat has recently retired as a GP in Darlington, Co.Durham after 37 years in the same practice and 41 years as a qualified doctor. He will continue to work as a GPSI Cardiology running a genetic lipid service for County Durham and Darlington Foundation Trust, and take up a role as Medical Director for OBEROI Consulting.

He has been a GPSI Cardiology for 26 years having undertaken a Postgraduate Diploma in Cardiology at Bradford University graduating with distinction. He started the first one stop diagnostic and integrated heart failure clinic in the UK in 2002 with local colleagues.

He has a PhD in research in heart failure diagnosis and management, which includes work on natriuretic peptides and has generated several publications that influenced guidelines and led to his recognition as an Honorary Professor at Durham University.

He holds various roles in CVD and research including the immediate past President of the Primary Care Cardiovascular Society (PCCS) which he was instrumental in reforming and current education and research lead, and GP Research Engagement lead for NENC CRN.

He has a passion for medical education and remains an active lecturer, tutor and researcher. He is a peer reviewer for most high impact Cardiovascular journals, BMJ, BJGP and research bodies. His work in community cardiology has been recognised with Fellowships from the RCGP, RCP London and RCP Edinburgh and the PCCS.

This promotional webinar has been developed and funded by the Boehringer Ingelheim & Lilly Alliance and is intended for Healthcare Professionals (HCPs) in the UK and Republic of Ireland only. Promotional information regarding Alliance products will be discussed in this webinar.

Prescribing information for Jardiance® (empagliflozin) for Great Britain Healthcare Professionals is available here

Prescribing information for Jardiance® (empagliflozin) for Northern Ireland Healthcare Professionals is available here

Prescribing information for Jardiance® (empagliflozin) for Healthcare Professionals in the Republic of Ireland is available here

Adverse event reporting information can be found at the bottom of this page.

 

Prices

This event is free for all delegates.

This promotional webinar has been developed and funded by the Boehringer Ingelheim & Lilly Alliance and is intended for Healthcare Professionals (HCPs) in the UK and Republic of Ireland only. Promotional information regarding Alliance products will be discussed in this webinar.

Prescribing information for Jardiance® (empagliflozin) for Great Britain Healthcare Professionals is available here

Prescribing information for Jardiance® (empagliflozin) for Northern Ireland Healthcare Professionals is available here

Prescribing information for Jardiance® (empagliflozin) for Healthcare Professionals in the Republic of Ireland is available here

Adverse event reporting information can be found at the bottom of this page.

 

Delegate Terms and Conditions

Data Protection

The data you have provided for this registration is stored and your name, organisation, job title and location details ONLY are shared with PCCS, the speaker faculty and funding company - see declaration - of this conference for attendance reporting purposes alone. LCW Consulting Ltd will use your data to contact you with regards to this conference only unless you have opted in for future events information. If you wish to cancel your registration, change your data options or require further information on our data policies please reply to this email or call via the registration number 0330 174 1090.

 

 

This promotional webinar has been developed and funded by the Boehringer Ingelheim & Lilly Alliance and is intended for Healthcare Professionals (HCPs) in the UK and Republic of Ireland only. Promotional information regarding Alliance products will be discussed in this webinar.

Adverse events should be reported. Reporting forms and information can be found at:

https://yellowcard.mhra.gov.uk/ (UK) and https://www.hpra.ie/homepage/about-us/report-an-issue  (Ireland). Adverse events should also be reported to Boehringer lngelheim Drug Safety on 0800 3281627 (freephone) (UK) or 012913960 (Ireland), Fax: +441344 742661 or by e-mail: PV_local_UK_lreland@boehringer-ingelheim.com  (Ireland).

PC-GB-109066 | October 2023


* An application has been made for this meeting to be accredited for Continuing Professional Development (CPD).

Other events